AtaiBeckley(NASDAQ) ATAI

AtaiBeckley Inc. makes new medicines for difficult mental health conditions. These products help patients who still have symptoms after standard treatments. The company focuses on rapid-acting care for depression and anxiety.

Developing New Mental Health Therapies

• BPL-003: Nasal spray for treatment-resistant depression (TRD); currently initiating Phase 3 clinical trials.
• VLS-01: Mouth-dissolving film for treatment-resistant depression; currently in Phase 2b clinical trials.
• EMP-01: Orally administered drug for social anxiety disorder (SAD); Phase 2a trials are now complete.
• Drug Discovery: Program identifying new molecules that provide medical benefits without causing hallucinations.

Strategic Shifts and Big Deals

• Entered a merger agreement with Eli Lilly and Company on July 15, 2026.
• Acquired Beckley Psytech in November 2025 to increase its research pipeline.
• Relocated its corporate domicile to Delaware in December 2025.
• Formed in 2025 by combining atai Life Sciences and Beckley Psytech Limited.

Specialized Science and Delivery

The company focuses on neuroplastogens, which are investigational compounds designed to help the brain repair connections. It uses a specialized subsidiary, Nualtis, to develop drug delivery films that dissolve in the mouth.

Tracking the Financial Path

• Total revenue was $1.7 million in the three months ended June 30, 2026, up 137% year over year.
• Research and development expenses reached $28.1 million in the quarter ended June 30, 2026, up 153% year over year.
• The company reported a net loss of $32.5 million for the three months ended June 30, 2026.
• Cash and cash equivalents totaled $168.8 million as of June 30, 2026.

Final Assessment

AtaiBeckley has evolved from a group of separate research projects into a unified clinical-stage biotechnology firm. Its pending merger highlights its shift from independent drug discovery to a corporate subsidiary.